Exosome-mediated MIR211 modulates tumor microenvironment via the DUSP6-ERK5 axis and contributes to BRAFV600E inhibitor resistance in melanoma by Lee, Bongyong et al.
Categories
Diseases or Functions 
Annotation
p-value
Predicted 
Activation 
State
Activati
on
z-score
Cell Cycle
M phase of tumor cell lines 0.0000 Increased 2.712
M phase 0.0000 Increased 2.591
M phase of cervical cancer cell 
lines
0.0000 Increased 2.126
Immunological Disease systemic autoimmune syndrome 0.0000 Increased 2.362
Cardiovascular System 
Development and 
Function
development of vasculature 0.0000 Increased 2.239
angiogenesis 0.0000 Increased 2.239
development of vascular 
endothelial cells
0.0000 Increased 2.226
cell movement of endothelial cells 0.0000 Increased 2.171
Cardiovascular Disease vascular lesion 0.0000 Increased 2.000
Connective Tissue 
Disorders, Inflammatory 
Disease, Organismal 
Injury and Abnormalities, 
Skeletal and Muscular 
Disorders
Rheumatic Disease 0.0000 Increased 2.152
Cellular Development, 
Cellular Growth and 
Proliferation
cell proliferation of carcinoma cell 
lines
0.0000 Increased 2.101
Cellular Movement cell movement of tumor cell lines 0.0000 Increased 2.087
The activation z-score measures the match between expected relationship direction and observed gene 
expression (≥2 is considered significant). 
Supplementary Table S1. Ingenuity Pathway Analysis (IPA) of mouse gene expression in MIR211-
overexpressign xenografts compared to A375 parental xenografts.
Gene
A375/211
(Reads)
A375
(Reads)
A375/211
(RPKM)
A375
(RPKM)
logFC
( 211/A375)
p-value FDR
Alpl 0.6 43.5 0.2 3.2 -3.7 0.0007 0.01
Amot 15.0 124.0 1.4 3.3 -1.4 0.0179 0.14
Angpt1 9.3 129.2 1.4 5.6 -2.2 0.0006 0.01
Angptl2 201.0 1407.0 38.1 76.0 -1.2 0.0118 0.10
Ankrd44 36.0 239.0 3.8 7.2 -1.1 0.0362 0.22
Aoah 13.1 103.7 2.9 6.6 -1.4 0.0293 0.19
C1qtnf3 277.4 2776.8 77.0 219.9 -1.7 0.0003 0.01
Cd74 83.8 2701.3 38.6 355.3 -3.4 0.0000 0.00
Chl1 87.0 560.0 7.3 13.4 -1.1 0.0284 0.19
Chsy1 78.0 715.0 12.2 31.9 -1.6 0.0014 0.02
Col5a1 1136.0 7956.0 88.2 176.3 -1.2 0.0100 0.09
Dmtf1 1.3 50.4 0.2 2.5 -4.0 0.0006 0.01
Dvl3 7.0 70.0 1.5 4.4 -1.7 0.0189 0.14
Efemp2 107.9 666.5 45.2 79.7 -1.0 0.0357 0.22
Epdr1 3.0 181.0 0.8 14.1 -4.3 0.0000 0.00
Esr1 11.5 117.7 1.2 3.5 -1.7 0.0071 0.07
Evc2 7.0 119.0 1.1 5.4 -2.5 0.0003 0.01
Farp1 18.0 194.0 2.4 7.4 -1.8 0.0016 0.02
Fbn2 77.0 922.0 4.8 16.4 -2.0 0.0001 0.00
Foxc1 0.0 41.0 0.0 1.9 -7.8 0.0001 0.00
Frs2 28.0 189.0 3.2 6.2 -1.2 0.0372 0.22
Get4 7.5 72.2 2.3 6.4 -1.6 0.0315 0.20
Gxylt2 4.0 99.0 1.4 10.1 -3.0 0.0001 0.00
Hs2st1 59.0 457.0 8.0 17.7 -1.3 0.0075 0.07
Itga11 25.0 203.0 3.3 7.7 -1.4 0.0110 0.09
Jarid2 0.4 68.1 0.0 2.2 -8.5 0.0000 0.00
Kdelc2 48.0 345.0 8.6 17.6 -1.2 0.0165 0.13
Lgr4 18.0 182.0 2.3 6.7 -1.7 0.0029 0.03
Lpar1 23.9 267.5 4.6 14.8 -1.9 0.0007 0.01
Lrrn4cl 21.0 152.0 5.3 11.0 -1.3 0.0329 0.21
Mgat3 10.0 160.0 1.4 6.4 -2.4 0.0001 0.00
P2rx7 6.4 56.5 1.6 4.1 -1.6 0.0361 0.22
Pde4a 8.3 72.6 1.2 2.9 -1.6 0.0271 0.18
Pik3ip1 8.0 94.0 2.3 7.8 -1.9 0.0045 0.05
Postn 314.0 3045.3 63.7 176.4 -1.7 0.0005 0.01
Prrx1 30.7 213.7 4.0 8.0 -1.2 0.0292 0.19
Ptprd 7.0 139.0 0.5 2.8 -2.7 0.0001 0.00
Ptprj 93.4 655.6 8.0 16.0 -1.2 0.0139 0.11
Rbl2 16.5 189.6 2.2 7.2 -1.9 0.0012 0.02
Rhot1 0.0 65.6 0.0 3.0 -8.5 0.0000 0.00
Rspo3 1.0 35.0 0.3 2.7 -3.4 0.0034 0.04
Senp3 12.0 114.2 3.2 8.7 -1.6 0.0090 0.08
Shc1 4.5 81.7 0.9 4.8 -2.4 0.0013 0.02
Sirt1 4.7 75.7 0.8 3.6 -2.3 0.0026 0.03
Ski 85.0 627.0 10.1 21.4 -1.3 0.0100 0.09
Smoc1 1.2 44.3 0.2 2.4 -3.8 0.0007 0.01
Tanc2 47.0 377.0 2.6 5.9 -1.4 0.0071 0.07
Tgfbr2 110.3 921.3 15.0 35.8 -1.5 0.0029 0.03
Tmem131 66.0 450.0 6.6 12.8 -1.2 0.0199 0.15
Tnfaip8 9.7 142.7 1.9 7.9 -2.2 0.0005 0.01
Trp53inp1 12.8 133.9 1.5 4.6 -1.8 0.0046 0.05
Ubp1 1.4 77.2 0.2 3.7 -4.6 0.0000 0.00
Wnk1 30.0 199.6 1.9 3.5 -1.1 0.0370 0.22
Zcchc14 78.0 729.0 7.9 21.0 -1.6 0.0012 0.02
Zfhx3 27.0 214.0 1.1 2.4 -1.4 0.0116 0.10
Zfhx4 24.0 398.0 1.1 5.3 -2.4 0.0000 0.00
Supplementary Table S2. Significantly downregulated genes in A375/211 xenografts predicted to be MIR211 
targets in the mouse.
A375/211 vs. A375 A375/211 vs. A375/211/PDK4 A375/211/PDK4 vs. A375
Ingenuity Canonical Pathways Z-score Ingenuity Canonical Pathways Z-score Ingenuity Canonical Pathways Z-score
Antioxidant Action of Vitamin C nd Antioxidant Action of Vitamin C nd Antioxidant Action of Vitamin C 2.000
BMP signaling pathway nd BMP signaling pathway nd BMP signaling pathway -2.236
cAMP-mediated signaling -2.000 cAMP-mediated signaling -2.111 cAMP-mediated signaling -1.000
Cardiac Hypertrophy Signaling -0.333 Cardiac Hypertrophy Signaling -2.309 Cardiac Hypertrophy Signaling 0.000
Colorectal Cancer Metastasis Signaling 0.218 Colorectal Cancer Metastasis Signaling -2.132 Colorectal Cancer Metastasis Signaling 0.000
Corticotropin Releasing Hormone 
Signaling
0.000
Corticotropin Releasing Hormone 
Signaling
-2.000 Corticotropin Releasing Hormone Signaling nd
CREB Signaling in Neurons 0.707 CREB Signaling in Neurons -2.121 CREB Signaling in Neurons -0.707
Cyclins and Cell Cycle Regulation 2.000 Cyclins and Cell Cycle Regulation nd Cyclins and Cell Cycle Regulation nd
Dopamine-DARPP32 Feedback in 
cAMP Signaling
-1.508
Dopamine-DARPP32 Feedback in cAMP 
Signaling
-2.236
Dopamine-DARPP32 Feedback in cAMP 
Signaling
-1.134
EIF2 Signaling -0.816 EIF2 Signaling -2.333 EIF2 Signaling 0.333
eNOS Signaling -1.732 eNOS Signaling -2.138 eNOS Signaling -0.302
ERK5 Signaling 2.236 ERK5 Signaling 0.000 ERK5 Signaling nd
Gαi Signaling -2.121 Gαi Signaling -1.633 Gαi Signaling nd
Gαq Signaling -2.333 Gαq Signaling -2.309 Gαq Signaling -0.577
Hypoxia Signaling in the Cardiovascular 
System
2.000
Hypoxia Signaling in the Cardiovascular 
System
nd
Hypoxia Signaling in the Cardiovascular 
System
nd
Interferon Signaling -2.449 Interferon Signaling -2.449 Interferon Signaling nd
P2Y Purigenic Receptor Signaling 
Pathway
0.000
P2Y Purigenic Receptor Signaling 
Pathway
-2.333 P2Y Purigenic Receptor Signaling Pathway 0.000
PPARα/RXRα Activation -2.121 PPARα/RXRα Activation -1.265 PPARα/RXRα Activation 1.342
Relaxin Signaling -0.816 Relaxin Signaling -2.121 Relaxin Signaling -0.378
RhoGDI Signaling 1.000 RhoGDI Signaling 1.508 RhoGDI Signaling -2.714
Role of NFAT in Regulation of the 
Immune Response
-1.000
Role of NFAT in Regulation of the 
Immune Response
-2.111
Role of NFAT in Regulation of the Immune 
Response
-0.632
SAPK/JNK Signaling 0.000 SAPK/JNK Signaling -2.449 SAPK/JNK Signaling 0.447
Sperm Motility -0.378 Sperm Motility 0.000 Sperm Motility -2.333
Synaptic Long-Term Depression -0.707 Synaptic Long-Term Depression nd Synaptic Long-Term Depression -2.646
Telomerase Signaling 2.121 Telomerase Signaling 0.000 Telomerase Signaling 0.000
Supplementary Table S3. Ingenuity pathway analysis (IPA) of differential gene expression in A375 
xenografts, MIR211-overexpressing xenografts, or MIR211/PDK4 co-expressing xenografts. 
Turquoise = activated; brown = inactivated. The activation z-score measures the match between expected 
relationship direction and observed gene expression (≥2 is considered significant).
Gene Set Name k/K p-value FDR
EPITHELIAL_MESENCHYMAL_TRANSITION 0.14 9.74E-29 4.87E-27
HYPOXIA 0.13 1.64E-24 4.09E-23
MTORC1_SIGNALING 0.12 8.44E-22 1.41E-20
GLYCOLYSIS 0.10 1.19E-16 1.49E-15
APOPTOSIS 0.09 4.40E-12 4.40E-11
TNFA_SIGNALING_VIA_NFKB 0.08 6.40E-12 5.33E-11
KRAS_SIGNALING_UP 0.06 1.06E-08 6.64E-08
MITOTIC_SPINDLE 0.06 1.06E-08 6.64E-08
P53_PATHWAY 0.06 1.06E-07 5.91E-07
ANGIOGENESIS 0.17 1.26E-07 6.32E-07
HALLMARK_UV_RESPONSE_DN 0.06 5.31E-07 2.41E-06
CHOLESTEROL_HOMEOSTASIS 0.09 6.10E-07 2.54E-06
G2M_CHECKPOINT 0.05 9.69E-07 3.46E-06
INFLAMMATORY_RESPONSE 0.05 9.69E-07 3.46E-06
SPERMATOGENESIS 0.06 3.41E-06 1.14E-05
E2F_TARGETS 0.05 7.98E-06 2.35E-05
IL2_STAT5_SIGNALING 0.05 7.98E-06 2.35E-05
ADIPOGENESIS 0.04 5.88E-05 1.63E-04
PI3K_AKT_MTOR_SIGNALING 0.06 7.15E-05 1.88E-04
FATTY_ACID_METABOLISM 0.04 9.03E-05 2.15E-04
UV_RESPONSE_UP 0.04 9.03E-05 2.15E-04
ESTROGEN_RESPONSE_LATE 0.04 3.83E-04 8.33E-04
MYC_TARGETS_V1 0.04 3.83E-04 8.33E-04
TGF_BETA_SIGNALING 0.07 4.46E-04 9.30E-04
ANDROGEN_RESPONSE 0.05 5.61E-04 1.12E-03
APICAL_JUNCTION 0.03 2.18E-03 3.76E-03
COMPLEMENT 0.03 2.18E-03 3.76E-03
MYOGENESIS 0.03 2.18E-03 3.76E-03
XENOBIOTIC_METABOLISM 0.03 2.18E-03 3.76E-03
COAGULATION 0.04 2.26E-03 3.76E-03
PROTEIN_SECRETION 0.04 3.78E-03 6.10E-03
BILE_ACID_METABOLISM 0.04 6.52E-03 1.02E-02
ALLOGRAFT_REJECTION 0.03 1.06E-02 1.52E-02
ESTROGEN_RESPONSE_EARLY 0.03 1.06E-02 1.52E-02
HEME_METABOLISM 0.03 1.06E-02 1.52E-02
PEROXISOME 0.03 3.15E-02 4.37E-02
Supplementary Table S4. Gene set enrichment analysis of differentially expressed genes in MIR211-
overexpressing A375 melanoma xenografts
Genomic Regiona Refseq Gene Peak IDb length p-value
Fold 
Enrichmentc
q-value
chr17:41843518-41843600 NM_004090 DUSP3 S23_peak_6881 172 9.76E-11 4.6 6.75E-07
chr17:41843600-41843689 NM_004090 DUSP3 S21_peak_5357 90 4.53E-06 2.8 0.009936
chr17:41845784-41845786 NM_004090 DUSP3 S21_peak_5358 108 4.98E-06 2.2 0.010662
chr17:41843753-41843833 NM_004090 DUSP3 S23_peak_6882 81 3.27E-05 2.3 0.041924
chr17:41845786-41845829 NM_004090 DUSP3 S23_peak_6883 106 1.78E-13 3.8 2.55E-09
chr8:29192622-29192688 NM_001394 DUSP4 S23_peak_14673 67 2.47E-05 1.8 0.032562
chr8:29193805-29193863 NM_001394 DUSP4 S23_peak_14674 59 1.08E-05 1.9 0.015964
chr8:29197663-29197726 NM_001394 DUSP4 S23_peak_14675 64 1.70E-06 2.4 0.003438
chr12:89743111-89743112 NM_001946 DUSP6 S21_peak_3124 56 2.35E-05 1.9 0.03739
chr12:89743166-89743175 NM_001946 DUSP6 S23_peak_3976 64 3.70E-05 1.8 0.046672
chr12:89745439-89745633 NM_001946 DUSP6 S21_peak_3125 195 5.60E-12 4.6 6.97E-08
chr12:89745908-89746077 NM_001946 DUSP6 S23_peak_3977 170 3.45E-07 3.4 0.000881
chr2:183962890-183962950 NM_080876 DUSP19 S21_peak_7263 61 2.22E-07 5.1 0.000726
chr11:102220458-102220491 NM_001166 BIRC2 S21_peak_2502 55 4.98E-06 2.2 0.010662
chr11:102220491-102220512 NM_001166 BIRC2 S21_peak_2502 55 4.98E-06 2.2 0.010662
chr11:102221400-102221459 NM_001166 BIRC2 S21_peak_2503 60 3.34E-11 6.6 3.48E-07
Supplementary Table S5. The enrichment of BIRC2 and DUSPs RNAs by Ago2-immunopurification
a hg19 genomic coordination
b S21 and S23 are two independent RIP-seq replicates.
C Fold enrichment compared to input.
MIR211 low expressors MIR211 high expressors
Cell line
MIR211
Ct
RNU48
Ct
-∆Ct
AUC
vemurafenib
resistance
Cell line
MIR211
Ct
RNU48
Ct
-∆Ct
AUC
vemurafenib
resistance
UACC-1097 38.4 22.9 -15.44 1.05 UACC-2994 27.8 21.6 -6.16 1.08
UACC-3291 38.3 22.9 -15.41 0.49 UACC-0903 28.6 23.1 -5.47 0.50
UACC-0558 38.4 23.0 -15.37 0.72 SK-MEL-119 27.9 22.5 -5.41 1.14
A375 38.1 23.1 -15.08 0.50 SK-MEL-217 27.2 22.1 -5.08 1.05
UACC-0502 38.3 23.4 -14.94 0.68 UACC-3312 25.3 21.9 -3.44 1.06
UACC-3337 37.3 22.7 -14.63 1.01 SK-MEL-113 25.4 22.3 -3.07 1.15
UACC-2331 36.8 22.6 -14.25 0.82 UACC-1649 25.9 23.0 -2.88 1.12
UACC-1118 37.3 23.4 -13.91 1.08 UACC-0257 25.3 22.6 -2.67 0.67
SK-MEL-2 36.6 22.9 -13.71 1.04 UACC-2427 27.7 25.7 -1.99 1.05
UACC-1237 35.9 22.2 -13.64 0.81 UACC-1120 24.0 22.1 -1.92 0.65
UACC-2641 35.3 22.3 -12.99 0.95 MeWo 24.2 22.5 -1.69 1.09
UACC-1729 35.9 22.9 -12.97 0.96 UACC-0091 23.7 22.8 -0.96 0.73
UACC-1113 35.3 22.4 -12.86 1.03 UACC-2972 22.9 22.1 -0.83 1.24
UACC-0612 35.4 22.6 -12.83 0.93 UACC-1308 23.0 22.6 -0.38 0.48
UACC-0647 35.6 22.9 -12.71 0.99 UACC-1940 25.6 25.5 -0.09 1.20
UACC-3074 34.6 22.1 -12.52 1.05 UACC-3093 24.3 24.4 0.08 1.01
UACC-1093 36.2 23.9 -12.28 0.93 SK-MEL-21 22.2 22.5 0.30 1.22
UACC-0952 34.9 23.3 -11.60 1.01
UACC-1469 34.7 23.2 -11.55 1.04
UACC-2496 34.8 23.6 -11.19 0.94
UACC-2851 33.5 22.9 -10.58 1.00
UACC-2610 33.1 22.5 -10.55 1.04
Supplementary Tabel S6. The level of MIR211 expression and vemurafenib resistance of various melanoma 
cell lines. (-DCt = -(Ct of MIR211 – Ct of RNU48) from qRT-PCR)
Supplementary Figure S1. qRT-PCR-detected changes in MIR211 in A375 and A375/211 cells. (unpaired 
student t-test, **** p ≤ 0.0001)
A B
A375
A375/211-c2
A375/211-c3
C
Supplementary Figure S2. Different MIR211-overexpressing A375 clones grown as xenografts in vivo.
(A) A375 amelanotic melanoma cells and their MIR211 overexpressing counterparts (A375/211-c2 and -c3)
were injected subcutaneously into the flanks of SCID mice and tumor volume measured with electronic
calipers until termination of the experiment at 12 days. A375/211 tumors were significantly larger and grew
more rapidly than the other tumors.
(B) Tumors were excised and weighed at the termination of the experiment at 12 days. MIR211-overexpressing
tumors were significantly heavier than either parental A375 xenografts. (unpaired student t-test, *** p < 0.001,
*** p < 0.0001)
(C) Photographs of subcutaneous tumor xenografts at the termination of the experiment at day 12. MIR211-
overepxressing xenografts were larger than parental controls.
Supplementary Figure S3. (A) qRT-PCR-detected changes in MIR210 in A375 and A375/210 cells (B) 
Tumors were excised and weighed at the termination of the experiment at 12 days. MIR210-overexpressing 
tumors were not significantly different to parental A375 xenografts. (unpaired student t-test, **** p ≤ 0.0001, 
ns: not significant) (C) Photographs of subcutaneous tumor xenografts at the termination of the experiment at 
day 12.
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Supplementary Figure S4. Ectopic expression of MIR211 in LOX-IMVI cells increased tumor growth.
LOX-IMVI stably expressing MIR211 cells were implanted in the flanks of SCID mice. (A) Tumor size was
measured and tumor volume was calculated as described in the Methods. (B) Mice were sacrificed at day 12
and tumors were excised and weighed. (LOX-IMVI/VO: LOX-IMVI with vector only; LOX-IMVI/211: cells
expressing MIR211, unpaired student’s t-test, * p ≤ 0.05, ** p ≤ 0.01)
Supplementary Figure S5. qRT-PCR-detected changes in PDK4 (A) in A375 and A375/211 cells (B) in A375 
and A375/211/PDK4 cells. (unpaired student t-test, ** p ≤ 0.01 **** p ≤ 0.0001) 
(C) Photographs of subcutaneous tumor xenografts at the termination of the experiment at day 12. The PDK4 
expression in A375/211 reduced the tumor growth.
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C
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Supplementary Figure S6. Ectopic expression of PDK4 reduces tumor growth in vivo.
(A) A375 melanoma cells and their PDK4 overexpressing counterparts (A375/PDK4) were injected
subcutaneously into the flanks of SCID mice and tumor volume measured with electronic calipers until
termination of the experiment at 26 days. A375/PDK4 tumors were significantly smaller and grew more slowly
than the other tumors. (student t-test, * p < 0.05, ** p< 0.01, *** p < 0.001)
(B) Tumors were excised and weighed at the termination of the experiment at 26 days. PDK4-overexpressing
tumors were significantly lighter than either parental A375 xenografts. (*** p < 0.001)
(C) Photographs of subcutaneous tumor xenografts at the termination of the experiment at day 26. PDK4 
overepxressing xenografts were smaller than parental controls.
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Supplementary Figure S7. qRT-PCR showing detection of MIR211, MIR16, and MIR23a (A) in exosomes 
and (B) cellular RNAs. (C) Differences between the human and mouse MIR211 sequences.
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Supplementary Figure S8. Gene Set Enrichment Analysis (GSEA) of differentially expressed human (A) and 
mouse (B) genes in A375/211 vs. A375 xenografts. Hypoxia and angiogenesis pathways were significantly 
enriched in both human and mouse cells. Mitochondrial Energy metabolism pathways were enriched, but not 
significantly.
AB
C
Supplementary Figure S9. Canonical Ingenuity Pathway Analysis (IPA) of differential gene expression in 
(A) A375 vs A375/211 (B) A375/211 vs A375/211/PDK4 and (C) A375/211/PDK vs A375 xenografts.
MEKK2/3MAPKKK
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Supplementary Figure S10. Schematic diagram of ERK5 pathway. BIRC2 and DUSPs are putative MIR211 
targets that negatively regulate ERK5 signaling. BIRC2 inhibits MEKK2/3 by ubiquitination. DUSPs inhibits 
ERK5 by dephosphorylation.
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Supplementary Figure S11
A. Luciferase reporter assays carrying either wild-type 3’UTR or a mutant with several nucleotides swapped in
the region corresponding to the MIR211 seed. When reporter plasmids were co-transfected with plasmids
expressing MIR211 into HEK-293T cells, the wild-type BIRC2, DUSP4, and DUSP19 reporters showed
reduced luciferase activity, while the mutant one did not. (Student t-test, ns: not significant, ** p ≤ 0.05, **** p
≤ 0.0001)
B. phosphor-ERK5 detection by western blot analysis of A375 cells transiently transfected with DUSPs
siRNAs.
C. phosphor-ERK5 detection by western blot analysis of A375/211 cells transiently transfected with plasmids
harboring each DUSP gene.
Supplementary Figure S12. qRT-PCR (A) and western blot (B) confirmation of DUSP6 knockdown by 
siRNA. 
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Supplementary Figure S13. (A) qRT-PCR confirmation of ERK5 knockdown by siRNA. (B) ERK5 
knockdown by siRNA reduced cell viability in A375/211 cells but not A375 cells. (unpaired student t-test, 
**** p ≤ 0.0001)
Low expressor High expressor
Supplementary Figure S14. The level of  MIR211 expression and vemurafenib resistance distinguished 
melanoma cell lines into two groups, MIR211 low expressors and high expressors. Low expressors showed the 
correlation between MIR211 expression and vemurafenib resistance, while high expressors did not.
Supplementary Figure S15. Targeted metabolomic analysis of A375/211 xenografts. 
(A) Schematic of the glycolytic and tricarboxylic cycle (TCA) pathways.
(B-D) In vivo targeted metabolomics of (B) glycolysis and glycolytic intermediates, (C) the TCA cycle, and 
(D) amino acids of A375 (black bars), A375/211 (gray bars), and A375/211/PDK4 (white bars) xenografts. 
(unpaired student t-test, ** p ≤ 0.05; ** p ≤ 0.01, *** p ≤ 0.001)
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